Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 9, 2022

UroGen Pharma Announces Upcoming 2022 Conferences

Business Wire September 7, 2022

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Business Wire August 11, 2022

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Business Wire July 27, 2022

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 3, 2022

UroGen Pharma to Present at Upcoming Investor Conferences

Business Wire May 18, 2022

UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer

Business Wire May 16, 2022

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

Business Wire May 13, 2022

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Business Wire May 10, 2022

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

GlobeNewswire May 10, 2022

UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

Business Wire May 3, 2022

UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

Business Wire March 29, 2022

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

GlobeNewswire March 22, 2022

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

Business Wire March 21, 2022

UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven

Business Wire March 8, 2022

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 4, 2022

UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022

Business Wire March 4, 2022

UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

Business Wire March 1, 2022

UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference

Business Wire February 28, 2022

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

Business Wire February 10, 2022